Vaccine for the Prevention of Cytomegalovirus (CMV)

The Potential Dangers of CMV

The dangers of Cytomegalovirus (CMV) make the research for its treatments and vaccines imperative. CMV is a prevalent virus spread through body fluids. Oftentimes CMV will show little to no symptoms in healthy adults and children. However, CMV can be detrimental and even deadly to infants as well as those suffering from a weakened immune system.

Babies born with CMV may present as healthy at birth or possibly exhibit low birth weight, but over time can begin to suffer from very serious conditions including microcephaly, intellectual disability, vision problems, seizures, enlarged or poorly functioning liver, digestive issues, pneumonia, jaundice, enlarged spleen, muscle weakness and lack of coordination.

Pregnant women who have already developed CMV antibodies will most likely not transmit the virus to their unborn fetus, but pregnant mothers with new CMV cases may. An amniocentesis can determine if an unborn child has contracted the CMV virus. Then, within three weeks and recurrently, that child should be tested by a physician for organ health. 

Those with weakened immune systems who contract the CMV virus, particularly those who have had organ, stem cell or bone marrow transplants, may experience serious problems with their lungs, vision, liver, stomach, intestines, esophagus and brain.

Preventing CMV

Currently, there is no cure for CMV. Once contracted, the CMV virus remains within the body for life with the potential to become dormant and reactivate in cycles. A vaccine for the prevention of CMV could protect our unborn children and those with weakened immune systems which put them at a greater risk of experiencing the harmful effects of the CMV virus. There is no vaccine for CMV at this time.

CMV vaccine research through clinical trials can provide us with a future where the prevention of this potentially devastating virus is possible; and a safe and effective CMV vaccine could protect our most vulnerable against the CMV infection.

Velocity Clinical Research conducts clinical research in an effort to safely protect people against infections. Clinical trials for CMV vaccines are currently being conducted. The purpose of this research is to help determine the safety and efficacy of an investigational CMV vaccine (a vaccine not yet approved by our country’s drug regulatory agency). These particular Velocity Clinical Research clinical trials are for the study of the CMV infection in women who have not had a prior CMV infection and to evaluate the safety in women who test positive for CMV due to prior exposure.

The Importance of Clinical Trial Volunteers

Development and Food and Drug Administration approval of a vaccine for the prevention of CMV would not be possible without the participation of clinical research volunteers. Together, Velocity Clinical Research CMV trial participants and the research and medical professionals at Velocity Clinical Research may contribute to the noble goal of finding a vaccine to help protect people, as well as future generations, against the CMV virus. 

Who Is Eligible to Volunteer

In order to participate in the Velocity Clinical Research CMV vaccine clinical trial, you must be a woman in good health between the ages of 16 and 40. If you are 20 years or older, you should also be in close contact with at least one child who is 5 years of age or younger for at least 8 hours a week. You cannot be pregnant or planning on becoming pregnant within the next 9 months.

Please note: If you are planning to get a COVID-19 vaccine, it must be administered at least 28 days prior to or after receiving the investigational vaccine for this clinical trial. You may receive an influenza vaccine if it is administered at least 14 days prior to or after receiving the investigational vaccine for this trial.

What to Expect as a Volunteer

Clinical trial volunteer screenings will include a medical history review, wellness check, pregnancy test and blood tests. There will be three injections in the upper arm over a six-month period, 15 total visits and 21 safety calls or eDiary safety checks. The total length of participation in this clinical trial is approximately 30 months.

This clinical trial, sponsored by Moderna, will include a sterile, salt water placebo. Neither the study doctor nor the volunteers will know which will receive the study vaccine or placebo and all participants will receive the same level of care. Each clinical trial participant has a 50% chance of receiving the clinical trial vaccine – which is not yet proven effective in preventing the CMV infection – and a 50% chance of receiving the placebo. Each volunteer will be closely monitored for side effects throughout the clinical trial and volunteers can stop participating at any time without providing a reason. Insurance is not required. Compensation for time will be provided.

If you are interested in becoming a clinical research volunteers in the hopes that we can defeat the CMV virus and control its spread, you can begin the process by contacting Velocity Clinical Research at 386-428-7730 Monday through Thursday from 7 a.m. to 5 p.m. or Friday from 7 a.m. to 12 p.m. 

Velocity Clinical Research

Velocity Clinical Research, world-renowned for its clinical trials, is dedicated to the maintenance of optimal health and medical advancements through clinical research. Velocity Clinical Research offers centuries of experience and a team of trusted, knowledgeable clinicians. Focused on clinical trials for over 250 years, Velocity Clinical Research has successfully completed over 5,000 clinical studies and cares for each and every clinical trial participant with compassion and kindness.

Velocity Clinical Research is conveniently located at 1410 S. Ridgewood Avenue in the lovely, vibrant town of Edgewater…and alongside historic New Smyrna Beach, a charming beachside community.